It is known that cell therapy is not free from risks (see our article on fraudulent cell therapy), and that possibilities are sometimes offered that do not comply with minimal safety regulations. In an attempt to avoid this, South Korea has amended its safety regulations for the use of drugs that use stem cells, obliging manufacturers to meet strict requirements for their production and thus avoid potential risks, while following rigorous safety protocols when they are to be used in patients. These regulations will come into force in 2017 (Nature Biotechnology 34; 125, 2016).
La entrada Fraudulent cell therapy. South Korea increases safety regulations aparece primero en Observatorio de Bioética, UCV.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.